Can a simple antibody infusion shield myeloma patients from infections?
NCT ID NCT06976476
First seen Nov 12, 2025 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study tests whether IgPro20 (HIZENTRA), a concentrated antibody solution given under the skin, can prevent infections in people with multiple myeloma who have low antibody levels due to bispecific antibody therapy. About 100 participants will either receive IgPro20 plus standard care or standard care alone. The goal is to see if infection rates drop over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
Mount Sinai Hospital
NOT_YET_RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IgPro20 (HIZENTRA), a subcutaneous immunoglobulin
What this could lead to
If it works, this could provide a way to reduce serious infections in multiple myeloma patients receiving bispecific antibody therapy, improving their quality of life and treatment tolerance.
What could go wrong
This is a phase 2 trial with only 100 participants, so results may not apply to all patients. The treatment is preventive, not curative, and carries risks like allergic reactions or infusion site issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.